For the year ending 2025-12-31, CHRS has $258,343K in assets. $197,329K in debts. $88,879K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 88,879 | |||
| Investments in marketable securities | 83,246 | |||
| Trade receivables, net | 17,815 | |||
| Tsa receivables, net | 603 | |||
| Inventory | 3,172 | |||
| Prepaid manufacturing | 6,758 | |||
| Other prepaids and current assets | 6,233 | |||
| Total current assets | 206,706 | |||
| Property and equipment, net | 1,345 | |||
| Intangible assets, net | 46,239 | |||
| Other assets, non-current | 4,053 | |||
| Total assets | 258,343 | |||
| Accounts payable | 9,915 | |||
| Accrued rebates, fees and reserves | 30,397 | |||
| Tsa payables and accrued liabilities | 65,065 | |||
| Accrued compensation | 14,579 | |||
| Accrued and other current liabilities | 20,430 | |||
| Total current liabilities | 140,386 | |||
| Term loan, non-current | 37,051 | |||
| Lease liabilities, non-current | 1,457 | |||
| Other liabilities, non-current | 18,435 | |||
| Total liabilities | 197,329 | |||
| Common stock (0.0001 par value shares authorized 300,000,000 shares issued and outstanding 121,154,925 and 115,614,548 at december 31, 2025 and december 31, 2024, respectively) | 12 | |||
| Additional paid-in capital | 1,444,166 | |||
| Accumulated other comprehensive loss | -195 | |||
| Accumulated deficit | -1,382,969 | |||
| Total stockholders' equity (deficit) | 61,014 | |||
| Total liabilities and stockholders' equity (deficit) | 258,343 | |||
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)